Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases (EPPIK)
Investigational therapy: Sparsentan
Therapeutic area: FSGS, IgAN, minimal change disease, IgA-associated vasculitis, Alport syndrome
Study type: Phase 2
Learn more: eppikclinicalstudy.com | NCT05003986
RESTORE Study
Investigational therapy: Chenodeoxycholic acid
Therapeutic area: CTX
Study type: Phase 3
Learn more: CTXrestore.com | NCT04270682
REPLACE Registry
Investigational therapy: Cholic acid
Therapeutic area: BASD; PBD-ZSD with liver involvement
Study type: Observational
Learn more: NCT03115086
COMPOSE Study
Investigational therapy: Pegtibatinase (TVT-058)
Therapeutic area: HCU
Study type: Phase 1/2
Learn more: hcuconnection.com | NCT03406611
Natural History Study of Homocystinuria Caused by Cystathionine Beta-synthase Deficiency
Therapeutic area: HCU
Study type: Observational
Learn more: hcuconnection.com | NCT03406611
HONUS Study: Humanistic Burden of FSGS and IGAN
Therapeutic area: FSGS; IgAN
Study type: Observational
Learn more: NCT05200871
DUPLEX Study
Investigational therapy: Sparsentan
Therapeutic area: FSGS
Study type: Phase 3
Learn more: fsgsduplex.com | NCT03493685
DUET Study
Investigational Therapy: Sparsentan
Therapeutic area: FSGS
Study type: Phase 2
Learn more: NCT01613118
PROTECT Study
Investigational therapy: Sparsentan
Therapeutic area: IgAN
Study type: Phase 3
Learn more: iganprotect.com | NCT03762850
CTX Prevalence Study
Therapeutic area: CTX among patients with early-onset idiopathic bilateral cataracts
Study type: Observational
Learn more: NCT02638220
MA-304
© 2022 Travere Therapeutics, Inc. All rights reserved. For US audiences. Chenodal®, Cholbam® and Total Care HUB® are registered trademarks of Travere Therapeutics, Inc. Thiola® and Thiola EC® are registered trademarks of Mission Pharmacal Company.
